Menopausal dyslipoproteinemia in breast carcinoma patients: a laboratory analysis

Authors

  • Harshal P. Narkhede Department of Biochemistry, Government Medical College, Nagpur, Maharashtra, India
  • Manohar G. Muddeshwar Department of Biochemistry, Government Medical College, Nagpur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20174425

Keywords:

Breast cancer, Cholesterol, HDL, Lipoproteins, LDL, Menopause

Abstract

Background: Seldom any precedent work has aimed to study the influence of age and menopausal status towards serum lipoproteins levels in breast cancer. Owing to influence of sex-steroids over lipid handling by oestrogen-dependent breast cells, their serum levels might reveal insinuating facts, if menopausal status-wise analysis is attempted. Ascertainment of serum lipid/lipoprotein aberrations in breast carcinoma; and substantiation of their behaviour with age and menopause among breast cancer and healthy subjects.

Methods: Laboratory analyses of serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low and very low density lipoproteins (LDL-c, VLDL-c) and triglycerides (TG) were done among breast cancer subjects (n=50) and healthy women (n=50) with respect to their age (3 sub-groups viz. 25-40, 41-55 and 56-75 years) and menopausal status. Grouped numerical data were subjected to intra- and inter-group comparisons using Student’s unpaired-‘t’-test and ANOVA with Post-Hoc comparisons using Tukey-HSD (Honestly-Significant-Difference) Test.

Results: Higher serum LDL-c and TC with lower HDL-c levels were observed among breast carcinoma subjects than healthy women (P=0.004, 0.003, 0.009 respectively). Serum LDL-c elevation in peri- and post-menopausal age (P=0.009), while lowered HDL-c specifically during post-menopausal age (0.004) were significantly evident in breast cancer subjects.

Conclusions: Breast carcinoma has obvious alliance with serum LDL-c, TC and HDL-c aberrations. LDL-c has specific variability during peri-menopausal and post-menopausal ages among breast cancer subjects. HDL-c alteration is mainly concerted for post-menopausal age; while total cholesterol could be a peril throughout. The odds of pooled effect of such aberrations in cancer causation cannot be underrated.

Author Biographies

Harshal P. Narkhede, Department of Biochemistry, Government Medical College, Nagpur, Maharashtra, India

Assistant Professor, Department of Biochemistry, Government Medical College and Hospital, Nagpur, Maharashtra, India.

Manohar G. Muddeshwar, Department of Biochemistry, Government Medical College, Nagpur, Maharashtra, India

Professor and Head, Department of Biochemistry, Government Medical College and Hospital, Nagpur, Maharashtra, India.

References

Buchwald H. Cholesterol inhibition, cancer and chemotherapy. Lancet. 1992;339:1154-6.

Soma MR, Corsini A, Paoletti A. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett. 1992;64-65:1-15.

Ray G, Hussain SA. Role of lipid, lipoprotein and vitamins in women with breast cancer. Clin Biochem. 2001;34:71-6.

Lane DM, Boatman KK, McCarthy WJ. Serum lipids and lipoproteins in women with breast masses. Breast Cancer Res Treat. 1995;34:161-9.

Hasija K, Bagga HK. Alterations of serum cholesterol and serum lipoprotein in breast cancer of women. Indian J Clin Biochem. 2005;20(1):61-6.

Gillmer MD. Mechanism of action/effects of androgens on lipid metabolism. Int J Fertil. 1992;37(2):83-92.

Lopes D, Sanchez MD, Shea-Eaton W, McLean MP. Estrogen Activates the High-Density Lipoprotein Receptor Gene via Binding to Estrogen Response Elements and Interaction with Sterol Regulatory Element Binding Protein-1A. Endocrinology. 2002;143(6):2155-68.

Owiredu WKBA, Donkor, Addai W, Amidu. Serum lipid profile of breast cancer patients. Pak J Biol Sci. 2009;12(4):332-8.

Lippman ME. Breast Cancer. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine 16th Ed. New Delhi:Mc-Graw Hill;2005:516-23.

Cholesterol reagent set (Kit insert). Thane (India): Accurex Biomedical Pvt. Ltd; 2009.

HDL-cholesterol reagent set (Kit insert). Thane (India): Accurex Biomedical Pvt. Ltd;2009.

Triglyceride reagent set (Kit insert). Thane (India): Accurex Biomedical Pvt. Ltd; 2009.

Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. New Delhi: Saunders Elsevier;2006:948.

De-Waard F, Comelis IP, Aoki K, Yoshida. Breast cancer incidence according to weight and height in two cities of the Netherlands and in Aichi prefecture, Japan. Cancer. 1977;40:1269-75.

Demers LM. The Adrenal Cortex. In: Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. New Delhi:Saunders Elsevier;2006:2003-52.

Rifai N, Warnick GR. Lipids Lipoproteins Apolipoproteins and Other Cardiovascular Risk Factors. In: Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. New Delhi:Saunders Elsevier;2006:904.

Kumar V, Green S, Stack G, Beny M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell. 1987;51:941-51.

Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993;15:48-65.

Araki E, Yamaguchi M, Yamamoto H, Inoue G, Tooma H, Ishikawa H et al. Serum lipids in patients with carcinoma and benign diseases of the breast. Jpn J Clin Oncol. 1980;10:211-4.

Lopez-Saez J, Martinez-Rubio JA, Alvarez MM, Carrera CG, Villar MD, Mier AGL, et al. Metabolic profile of breast cancer in a population of women in Southern Spain. Open Clin Cancer J. 2008; 2:1-6.

Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004;96(15):1152-60.

Downloads

Published

2017-09-23

Issue

Section

Original Research Articles